SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation-Reference-Cited by-同舟云学术

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Published:2021-01 Issue:1 Volume:77 Page:94-109
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Tuttle Katherine R.,Brosius Frank C.,Cavender Matthew A.,Fioretto Paola,Fowler Kevin J.,Heerspink Hiddo J.L.,Manley Tom,McGuire Darren K.,Molitch Mark E.,Mottl Amy K.,Perreault Leigh,Rosas Sylvia E.,Rossing Peter,Sola Laura,Vallon Volker,Wanner Christoph,Perkovic Vlado

Publisher

Elsevier BV

Subject

Nephrology

Reference102 articles.

1. National Diabetes Statistics Report, 2020,2020

2. IDF Diabetes Atlas,2019

3. KDOQI clinical practice guideline for diabetes and CKD: 2012 update;Am J Kidney Dis,2012

4. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database;Packham;Am J Kidney Dis,2012

5. Diabetic kidney disease: challenges, progress, and possibilities;Alicic;Clin J Am Soc Nephrol,2017

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis;Pharmacological Research;2024-09

2. Relationship between sodium‐glucose cotransporter 2 inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation;Journal of Cardiovascular Electrophysiology;2024-07-11

3. Association of plasma ceramide with decline in kidney function in patients with type 2 diabetes;Journal of Lipid Research;2024-06

4. Chronic Kidney Disease in Patients with Hip Fracture: Prevalence and Outcomes;International Journal of Clinical Practice;2024-05-09

5. Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial;Diabetes, Obesity and Metabolism;2024-05-03